Keros Therapeutics initiated with an Outperform at William Blair

William Blair initiated coverage of Keros Therapeutics with an Outperform rating and $81 fair value. The analyst believes KER-012 has the potential to be the main value driver for Keros, with the results of the TROPOS Phase II trial in pulmonary arterial hypertension expected in 2025. To date, KER-012 has not shown hemoglobin increases or risk of bleeding, including at supraphysiological doses in nonhuman primates, which will result in a superior therapy option for pulmonary arterial hypertension patients, the analyst tells investors in a research note.